Effects of G-CSF and antibiotic prophylaxis in a 2 x 2 factorial design on outcome in septic rats

Inflammation Research

Volumn 53, Issue SUPPL. 2, 2004, Pages

  Bauhofer, A ^a   Celik, I ^a   Plaul, U ^a   Wulf, H ^a   Torossian, A ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Cefuroxime metronidazole; Clinic modelling randomised trial; Granulocyte colony stimulating factor (G CSF); Ofloxacin metronidazole; Sepsis

Indexed keywords

CEFUROXIME; GRANULOCYTE COLONY STIMULATING FACTOR; METRONIDAZOLE; OFLOXACIN;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC PROPHYLAXIS; ARTICLE; COMPARATIVE STUDY; DRUG EFFICACY; MALE; NONHUMAN; PERITONEUM; PROTEIN ANALYSIS; PROTEIN FUNCTION; RAT; SEPSIS; SURVIVAL; TREATMENT OUTCOME;

ABDOMEN; ANIMALS; ANTIBIOTIC PROPHYLAXIS; CEFUROXIME; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; METRONIDAZOLE; OFLOXACIN; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; SEPSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 4344684594     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J and Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-10.
2. Nelson S. Role of granulocyte colony-stimulating factor in the immune response to acute bacterial infection in the nonneutropenic host: an overview. Clin Infect Dis 1994; 18: 197-204.
3. Weiss M, Gross-Weege W, Schneider M, Neidhardt H, Liebert S, Mirow N et al. Enhancement of neutrophil function by in vivo filgrastim treatment for prophylaxis of sepsis in surgical intensive care patients. J Crit Care 1995; 10: 21-6.
4. Goergen I, Hartung T, Leist M, Niehoerster M, Tiegs G, Uhlig S et al. Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor alpha. J Immunol 1994; 149: 918-24.
5. Gough A, Clapperton M, Rolando N and Foster AVM. Granulocyte-colony- stimulating factor in diabetic foot infection. Lancet 1998; 351: 370.
6. Garcia-Carbonero R, Mayordomo JI, Tornamira MV, Lopez-Brea M, Rueda A, Guillem V et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 2001; 93: 31-8.
7. Bauhofer A, Lorenz W, Celik I, Stinner B, Solovera J and Lorijn R. Haematopoetic cytokines, G-CSF and abdominal surgery. In:Schein, M., Wise, L., eds. Cytokines and the abdominal surgeon. 1998; 117-41.
8. Bauhofer A, Torossian A, Middeke M, Plaul U, Schütz P, Stinner B et al. Positive effects of G-CSF are dependent on the antibiotic regime: evaluation in rats with peritoneal contamination and infection using the concept of clinic modelling randomized trials. World J Surg 2004 (in press).
9. Lorenz W, Reimund K-P, Weitzel F, Celik I, Kurnatowski M, Schneider C et al. Granulocyte colony-stimulating factor prophylaxis before operation protects against lethal consequences of postoperative peritonitis. Surgery 1994; 116: 925-34.
10. Grigg AP, Roberts AW, Raunow H, Houghton S, Layton JE, Boyd AW et al. Optimizing dose and scheduling of Filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1998; 86: 4437-45.
11. Tanaka H and Kaneko T. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor in the rat. Drug Metabolism and Disposition 1991; 19: 200-4.
12. Bauhofer A, Lorenz W, Stinner B, Rothmund M, Koller M, Sitter H et al. Granulocyte-colony stimulating factor in the prevention of postoperative infectious complications and sub-optimum recovery from operation in patients with colorectal cancer and increased preoperative risk (ASA 3 and 4). Protocol of a controlled clinical trial developed by consensus of an international study group. Part two: design of the study. Inflamm Res 2001; 50: 187-205.
13. Lord BI, Gurney H, Chang J, Thatcher N, Crowther D and Dexter TM. Haematopoetic cell kinetics in humans treated with rGM-CSF. Int J Cancer 1992; 50: 26-31.
14. Bauhofer A, Lorenz W and Stinner B. Improvement of quality of life by G-CSF prophylaxis in high risk patients with colorectal cancer surgery - results of a randomised trial. Shock 2004; 21 Suppl: 39.
15. Friedman LM, Furberg CD and DeMets DL. Fundamentals of clinical trials. 1985; 2nd: 1-302.
16. Bishop MR, Tarantolo SR, Geller RB, Lynch JC, Bierman PJ, Pavletic ZS et al. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 2000; 96: 80-5.
17. Ishikura H, Uedono Y, Yamagami K, Arai T, Takeyama N and Tanaka T. Activation of neutrophil function by recombinant human granulocyte colony-stimulating factor improves the survival of rats with peritonitis. Surg Today 1996; 26: 694-9.
18. Torossian A, Rühlmann S, Middeke M, Lorenz W, Wulf H and Bauhofer A. Deleterious effects of mild hypothermia in septic rats are ameliorated by granulocyte-colony stimulating factor. Anesthesiology 2003; 99: 1087-92.
19. Edmiston CE, Goheen MP, Kornhall S, Jones FE and Condon RE. Fecal peritonitis: microbial adherence to serosal mesothelium and resistance to peritoneal lavage. World J Surg 1990; 14: 176-83.
20. Baker CC, Caudry IH, Gaines HO and Baue AE. Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. Surgery 1983; 94: 331-5.
21. Vianna RC, Gomes RN, Bozza FA, Amancio RT, Bozza PT, David CM et al. Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release. Shock 2004; 21: 115-20.
22. Turnbull IR, Javadi P, Buchman TG, Hotchkiss RS, Karl IE and Coopersmith CM. Antibiotics improve survival in sepsis independent of injury severity but do not change mortality in mice with markedly elevated interleukin 6 levels. Shock 2004; 21: 121-5.
23. Hahn T, Gross O, Gottesman I, Leibovitz E and Barak Y. The effect of quinolones on human hematopoietic progenitors and on cytokine production by mononuclear leucocytes. 16th International Congress of Chemotherapy Jerusalem, Israel 1989.
24. McKenna PJ, Nelson S and Andresen J. Filgrastim (rhuG-CSF) enhances ciprofloxacin uptake and bactericidal activity of human neutrophils in vitro. Am J Respir Crit Care Med 1996; 153: A535.
25. Saba R, Guler M, Inan D, Ogunc D, Atalay S, Mamikoglu L et al. The effect of granulocyte colony-stimulating factor in the treatment of Escherichia coli peritonitis with or without ceftriaxone in a nonneutropenic rat model. Surg Today 2003; 33: 504-8.
26. Celik I, Nies C, Lorenz W, Sitter H, Stinner B, Krack W et al. Influence of histamine H1+H2 receptor antagonists on abdominal infections following minimally invasive versus conventional surgery: studies in large samples of rats following the new concept of clinic modelling randomised trials (CMRT). Inflamm Res 1999; 48 Suppl 1: S51-2.
27. Lenhoff S and Olofsson T. Effects of immunosuppressive drugs and antibiotics on GM-CSF and G-CSF secretion in vitro by monocytes, T lymphocytes and endothelial cells. Br J Haematol 1996; 95: 33-8.
28. Nadai M, Matsuda I, Wang L, Itoh A, Naruhashi K, Nabeshima T et al. Granulocyte colony-stimulating factor enhances endotoxin-induced decrease in biliary excretion of the antibiotic cefoperazone in rats. Antimicrob Agents Chemother 1998; 42: 2178-83.